Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 8/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77073 | 0.92 | CYP3A4 (0.75) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL1823367 | 0.88 | CYP2C19 (0.71) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL298612 | 0.87 | CYP2C19 (0.51) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL299480 | 0.85 | CYP3A4 (0.75) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL287906 | 0.83 | CYP2C19 (0.66) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL1086108 | 0.83 | CYP2C19 (0.81) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL1817466 | 0.83 | CYP2C19 (0.79) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL297522 | 0.83 | CYP3A4 (0.80) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL1816944 | 0.83 | CYP2C19 (0.79) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL1818579 | 0.82 | CYP2C19 (0.77) | CYP2C19CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2012-06-28 | — | — | US | claimed |
| US-8129404-B2 | Compounds and uses thereof | PLEXXIKON INC. (US) | 2012-03-06 | — | — | US | claimed |
| EP-2406260-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2012-01-18 | — | — | EP | claimed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | claimed |
| WO-2010104973-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9296811-B2 | Methods for treating a tumor using an antibody that specifically binds HMW-MAA | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-21 | — | — | US | disclosed |
| US-8771687-B2 | Methods for treating a tumor using an antibody that specifically binds GRP94 | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2646054-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130259873-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS HMW-MAA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-10-03 | — | — | US | disclosed |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2010104973-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104973-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104973-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | BRAF, PKD1, RAF1 | CYP2C19 1818/4885CYP2C9 1862/4885CYP3A4 3037/4885 |
| US-20130259873-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS HMW-MAA | PA2G4, BRAF, HSPA1A | CYP2C19 4751/4885CYP2C9 4793/4885CYP3A4 4504/4885 |
| US-20140234324-A1 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 | LY96, HSPA2, BRAF | CYP2C19 4766/4885CYP2C9 4865/4885CYP3A4 4791/4885 |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | BRAF, PKD1, RAF1 | CYP2C19 1818/4885CYP2C9 1862/4885CYP3A4 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.